Boston Scientific Corp

BSX-N

NYSE:BSX

41.55
0.06 (0.14%)
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional ...
More at Wikipedia

Analysis and Opinions about BSX-N

Signal
Opinion
Expert
Chart
HOLD
HOLD
April 23, 2021
Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.
Show full opinionHide full opinion
Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.
Darren Sissons
Price
$42.610
Owned
Yes
BUY
BUY
April 21, 2021

Hit a 52-week high today. This sector (medical devices) has reported very strong reports, such as Intuitive Surgical.

Show full opinionHide full opinion

Hit a 52-week high today. This sector (medical devices) has reported very strong reports, such as Intuitive Surgical.

Jim Cramer - Mad Money
Price
$42.310
Owned
Unknown
DON'T BUY
DON'T BUY
April 14, 2021

Liked it better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Good management that will learn from the past. Volumes in medical devices are not recovering as he expected. He owns Abbott Labs instead, a diversified player with a very strong balance sheet. You could also look at the dental space.

Show full opinionHide full opinion

Liked it better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Good management that will learn from the past. Volumes in medical devices are not recovering as he expected. He owns Abbott Labs instead, a diversified player with a very strong balance sheet. You could also look at the dental space.

David Fingold
Price
$39.665
Owned
No
HOLD
HOLD
February 11, 2021
Cardiovascular-related devices, and they're doing very well. Raised equity, and pulled a device from market due to potential safety issues. Took a bit of a hit on earnings. Likes it, but he's watching closely as it becomes more concentrated.
Show full opinionHide full opinion
Cardiovascular-related devices, and they're doing very well. Raised equity, and pulled a device from market due to potential safety issues. Took a bit of a hit on earnings. Likes it, but he's watching closely as it becomes more concentrated.
Paul MacDonald
Price
$38.770
Owned
Yes
TOP PICK
TOP PICK
December 1, 2020
One of the largest medical device manufacturers. New management has cleaned things up. Stock hit by a heart valve recall. Substantial upside. No dividend. (Analysts’ price target is $42.96)
Show full opinionHide full opinion
One of the largest medical device manufacturers. New management has cleaned things up. Stock hit by a heart valve recall. Substantial upside. No dividend. (Analysts’ price target is $42.96)
Bruce Murray
Price
$33.860
Owned
Yes
BUY
BUY
November 23, 2020
It has been impacted. From 2013 to 2019 they could do no wrong, then there were a few hiccups. They discontinued one of their hard-valve products that will impact their growth over the next 3-4 years. If you think management can continue to execute and hit a couple of home runs, then stick with it. He would consider it a buy at these levels.
Show full opinionHide full opinion
It has been impacted. From 2013 to 2019 they could do no wrong, then there were a few hiccups. They discontinued one of their hard-valve products that will impact their growth over the next 3-4 years. If you think management can continue to execute and hit a couple of home runs, then stick with it. He would consider it a buy at these levels.
Jamie Murray
Price
$33.330
Owned
Yes
BUY
BUY
October 7, 2020

BSX vs. BDX Owns Boston Scientific instead of BDX. BSX has a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. Well known for innovation.

Show full opinionHide full opinion

BSX vs. BDX Owns Boston Scientific instead of BDX. BSX has a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. Well known for innovation.

Jennifer Radman
Price
$40.355
Owned
Yes
BUY
BUY
August 25, 2020
Allan Tong’s Discover Picks It trades at a 32x PE, but pays no dividend. Despite the spring lockdown, BSX offers revenue growth YOY of 9.28% though the one-year total return is -5.42%. It beat EPS in three of its last four earnings periods, and the market expects its EPS to leap from 8 cents in Q2 to 24 cents in Q3 (to reported on Oct. 21). Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
Show full opinionHide full opinion
Allan Tong’s Discover Picks It trades at a 32x PE, but pays no dividend. Despite the spring lockdown, BSX offers revenue growth YOY of 9.28% though the one-year total return is -5.42%. It beat EPS in three of its last four earnings periods, and the market expects its EPS to leap from 8 cents in Q2 to 24 cents in Q3 (to reported on Oct. 21). Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
BUY
BUY
August 24, 2020
BSX vs. CCI One of his biggest holdings and fully believes in it. They suffered because their medical devices are non-essential, but they will recover nicely in time. Crown Castle is very different, a real estate play for cell phone towers, which will see strong growth, but the PE is very high given this expected growth. There's little risk though. You can buy both stocks.
Show full opinionHide full opinion
BSX vs. CCI One of his biggest holdings and fully believes in it. They suffered because their medical devices are non-essential, but they will recover nicely in time. Crown Castle is very different, a real estate play for cell phone towers, which will see strong growth, but the PE is very high given this expected growth. There's little risk though. You can buy both stocks.
Bruce Murray
Price
$38.660
Owned
Yes
TOP PICK
TOP PICK
July 14, 2020
One of the fastest-growiong medical device companies. This has been unfairly beaten up during the pandemic with a delay in elective surgeries. When those operations return, BSX should do well. (Analysts’ price target is $42.96)
Show full opinionHide full opinion
One of the fastest-growiong medical device companies. This has been unfairly beaten up during the pandemic with a delay in elective surgeries. When those operations return, BSX should do well. (Analysts’ price target is $42.96)
Jamie Murray
Price
$34.810
Owned
Yes
COMMENT
COMMENT
March 5, 2020
Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.
Show full opinionHide full opinion
Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.
Darren Sissons
Price
$37.460
Owned
Unknown
TOP PICK
TOP PICK
February 24, 2020
They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)
Show full opinionHide full opinion
They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)
BUY WEAKNESS
BUY WEAKNESS
January 10, 2020
Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.
Show full opinionHide full opinion
Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.
Brian Acker, CA
Price
$45.900
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
September 16, 2019

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

Show full opinionHide full opinion

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

Bruce Murray
Price
$41.940
Owned
Yes
BUY
BUY
July 17, 2019
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
Show full opinionHide full opinion
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
Paul MacDonald
Price
$42.240
Owned
Yes
Showing 1 to 15 of 40 entries

Boston Scientific Corp(BSX-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 8

Stockchase rating for Boston Scientific Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Boston Scientific Corp(BSX-N) Frequently Asked Questions

What is Boston Scientific Corp stock symbol?

Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N

Is Boston Scientific Corp a buy or a sell?

In the last year, 8 stock analysts published opinions about BSX-N. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Boston Scientific Corp.

Is Boston Scientific Corp a good investment or a top pick?

Boston Scientific Corp was recommended as a Top Pick by Darren Sissons on 2021-04-23. Read the latest stock experts ratings for Boston Scientific Corp.

Why is Boston Scientific Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Boston Scientific Corp worth watching?

8 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.

What is Boston Scientific Corp stock price?

On 2021-05-14, Boston Scientific Corp (BSX-N) stock closed at a price of $41.55.